DDInter1233 DDInter462
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Mitotane {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Cytochrome P450 3A4 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Dabrafenib
Mitotane {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Mitotane {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Dabrafenib
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Cytochrome P450 3A4 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Mitotane {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Mitotane {u} (Compound) causes {v} (Side Effect) Skin toxicity
Skin toxicity {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Mitotane {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is regulated by {v} (Gene) AGL
AGL {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Mitotane {u} (Compound) resembles {v} (Compound) Delorazepam
Delorazepam {u} (Compound) resembles {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Mitotane (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is upregulated by Dabrafenib (Compound)
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class) and Cytochrome P450 3A4 Inducers (Pharmacologic Class) includes Dabrafenib (Compound)
Mitotane (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dabrafenib (Compound)
Mitotane (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Dabrafenib (Compound)
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class) and Cytochrome P450 3A4 Inducers (Pharmacologic Class) includes Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Mitotane (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Mitotane (Compound) causes Skin toxicity (Side Effect) and Skin toxicity (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Mitotane (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is regulated by AGL (Gene) and AGL (Gene) is upregulated by Dabrafenib (Compound)
Mitotane (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib